The study shows selective tumor uptake of IL12-7NP2 and potent antitumor activity as single agent and in combination with immune checkpoint inhibitors. The product is well tolerated when administered to non-human primates.
News & Events
Philogen announces publication of IL12-7NP2 (an Interleukin-12 fusion protein against Fibroblast Activation Protein) in Journal for Immunotherapy of Cancer.
Last News & Events
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.